Clinical Trial

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-23; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT07002112
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Collaborators: Nanjing Legend Biotech Co.
Conditions Relapsed/Refractory B-cell Malignancies
Enrollment 30 participants
Start Date 2025-05-23
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-14